Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
some people are concerned about side effects, and others may not qualify for a prescription or prefer to explore non-medication options first
According to both experts, products featuring copper peptides have a number of benefits for the skin
Inject into fatty tissue using a fine-gauge insulin needle
